Congress Materials – Winter Clinical Miami 2025

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Long-Term Effectiveness of Guselkumab vs. Other Biologic Therapies Among Plaque Psoriasis Patients in the CorEvitas Psoriasis Registry

Bruce E. Strober, April W. Armstrong, Timothy Fitzgerald, Katelyn Rowland, Olivia Choi, Daphne Chan, Alvin H. Li, Adam P. Sima, Thomas Eckmann, Sandra Main, Mark G. Lebwohl

 

View poster

Shadows of Inflammation: Exploring Post-inflammatory Pigment Changes in Psoriasis in VISIBLE, a Phase 3b Randomized Controlled Study of Guselkumab for Moderate-to-severe Plaque Psoriasis Dedicated to People of Color

Andrew Alexis, Amy McMichael, Tina Bhutani, Mona Shahriari, Olivia Choi, Theodore Alkousakis, Katelyn Rowland, Adrian O. Rodriguez, Geeta Yadav, Jensen Yeung, Tony Ma, Nastaran Abbarin, Daphne Chan, Chesahna Kindred, Neelam Vashi, Pearl Grimes, Seemal R. Desai, Susan C. Taylor

 

View poster

SPECTREM: Guselkumab Demonstrates Consistent Significant Clearance at Week 16 Across the Full Range of Low Body Surface Area, Moderate Psoriasis with Special Sites Involvement

Linda Stein Gold, Bruce Strober, April W. Armstrong, Theodore Alkousakis, Kim A. Papp, Richard Langley, Olivia Choi, Daphne Chan, Jenny Jeyarajah, Vlada Groysman, Mark G. Lebwohl

 

View poster

Sustained Improvements in Psoriasis Area and Severity Index and in Percent Body Surface Area of Psoriasis With JNJ-77242113 in Patients With Moderate-to-Severe Plaque Psoriasis: Treat-to-Target Analyses in the FRONTIER 1 & 2 Studies

Kim A. Papp, Laura K. Ferris, Andreas Pinter, Phoebe Rich, Ronald B. Vender, Andrew E. Pink, Takayuki Ota, Yaung-Kaung Shen, Shu Li, Amy M. DeLozier, Ya-Wen Yang, Robert Bissonnette

 

View poster